NetScientific
NetScientific plc (AIM: NSCI) is an investment and commercialisation group with an international portfolio of innovative life science, sustainability and technology companies. NetScientific identifies, invests in, and builds high growth companies in the UK and internationally. The company adds value through the proactive management of its portfolio, progressing to key value inflection points, and delivering investment returns through partial or full liquidity events. NetScientific differentiates itself by employing a capital-light investment approach, making judicial use of its balance sheet and syndicating investments through its wholly owned VC subsidiary, EMV Capital. The group secures a mixture of direct equity stakes and carried interest stakes in its portfolio of companies, creating a lean structure that can support a large portfolio. NetScientific is headquartered in London, United Kingdom, and is admitted to trading on AIM, a market operated by the London Stock Exchange.
Q-BOT Ltd, a Wandsworth, London, UK-based developer of a robotics platform that can access, survey, evaluate and apply treatments in a wide range of industries and applications. The company is funded through a combination of government grants, private investment and sales revenue, and has been supported by Climate-KIC, The Technology Strategy Board and The Department for Energy and Climate Change.
Q-BOT Ltd, a Wandsworth, London, UK-based developer of a robotics platform that can access, survey, evaluate and apply treatments in a wide range of industries and applications. The company is funded through a combination of government grants, private investment and sales revenue, and has been supported by Climate-KIC, The Technology Strategy Board and The Department for Energy and Climate Change.
EpiBone is a pioneering regenerative medicine company at the forefront of bone and cartilage repair. Leveraging the power of stem cells, biomimicry, and 3D fabrication, they are developing a pipeline of innovative products with enormous potential to revolutionize orthopedic repair. Their lead product, a living, anatomically precise 3D bone graft, completed its Phase I/IIa clinical trial in August 2023. The rest of their pipeline focuses on cartilage repair, and includes an allogeneic osteochondral plug, whose IND was approved in July 2023. Their cartilage portfolio also includes an injectable cartilage filler that was partly funded by the Department of Defense.
Sofant is developing a low cost RF MEMS technology that solves power consumption and heat problems in high frequency phased array antenna systems.
PointGrab Ltd. develops machine learning technology installed in optical IoT sensors for commercial Real Estate. The sensors enables Companies to better manage their real estate, increase efficiency and cut Real Estate costs, while keeping Employees' privacy and welfare. PointGrab is considered marker leader in providing occupancy and smart building features in commercial Real Estate.
SageTech is recycling inhalational anaesthetic agents using patented technology to generate significant cost and environmental benefits for healthcare providers. SageTech has developed, prototyped, and patented systems to capture, extract and purify inhalational anaesthetic emissions, creating a circular economy for a formerly wasteful pharmaceutical product
EMV Capital is an award-winning VC investor specialising in early stage high-growth deep tech companies in the life science, sustainability and industrials sectors in the UK and internationally. EMV Capital develops unique investment strategies for each portfolio company, drawing on its EIS fund and extensive network of private investors, family offices, institutions, and corporate VCs. Delivery and successful execution of these investment strategies enables innovative portfolio companies to raise funding to drive transformational growth. EMV Capital is a wholly owned subsidiary of NetScientific plc (AIM:NSCI), a life sciences and technology commercialisation and investment group. EMV Capital has a multi-disciplinary team of specialist investors, portfolio managers, capital raisers, legal, finance, marketing and support staff. The company is focused on primary and secondary investments, through debt and/or equity.
ProAxsis Ltd. specialises in the development of laboratory-based immunoassays and rapid point-of-care tests for the capture, detection and measurement of active protease biomarkers of disease. Its rapid and easy-to-use tests incorporate patented “ProteaseTags®”; smart molecules which trap an active protease within a complex biological sample and enable a visual readout of its presence. A number of active protease species have been extensively validated as biomarkers of disease activity in areas such as cancer and infection, in addition to respiratory diseases such as bronchiectasis, cystic fibrosis and COPD. Its first immunoassay, for the specific measurement of active neutrophil elastase as a biomarker of lung infection and inflammation, was registered with a European CE Mark in 2016.
Nuada is a vertically integrated pure-play carbon capture company that is poised to decarbonise heavy industries through its next generation point-source capture technology. The company builds energy-efficient CO2 filtration machines that enable industrial emitters in hard-to-abate sectors to achieve their Net Zero targets whilst minimising the impact on their bottom line.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.